John W. Eikelboom
Duke University
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Atrial Fibrillation Management and Outcomes
Strong evidence · 14 supporting papers · latest 2026
Antiplatelet Therapy and Cardiovascular Diseases
Strong evidence · 5 supporting papers · latest 2026
Inflammasome and immune disorders
Solid evidence · 1 supporting paper · latest 2026
Intracerebral and Subarachnoid Hemorrhage Research
Solid evidence · 3 supporting papers · latest 2026
Health Systems, Economic Evaluations, Quality of Life
Solid evidence · 3 supporting papers · latest 2026
Acute Kidney Injury Research
Solid evidence · 2 supporting papers · latest 2026
Chronic Kidney Disease and Diabetes
Solid evidence · 2 supporting papers · latest 2026
Acute Myocardial Infarction Research
Solid evidence · 2 supporting papers · latest 2026
Publications (15)
Non‐contrast CT Markers of Hematoma Expansion and Andexanet Response in Factor Xa Inhibitor‐Associated Intracerebral Hemorrhage: An Analysis from ANNEXa ‐I Trial
2026DOIPMID 42708556
Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF Analysis
2026DOIPMID 42549517
DOAC score among patients receiving Vitamin K antagonists
2026DOIPMID 42336120
Discordance in estimated kidney function by different equations and outcomes in patients with atrial fibrillation on oral anticoagulation: a COMBINE-AF analysis
2026DOI
Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial Fibrillation
2026DOIPMID 42489381
NT-proBNP in relation to clinical characteristics and cardiovascular outcomes in non-anticoagulated patients with atrial fibrillation
2026DOIPMID 42608180
Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation
2026DOIPMID 42343976
Interpreting apparent differences among the major colchicine trials for cardiovascular prevention: A descriptive compatibility analysis
2026DOIPMID 42435998
Left Atrial Appendage Thrombosis in Patients With Atrial Fibrillation
2026DOIPMID 42695997
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
2026DOIPMID 42240165
A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial
2026DOIPMID 42700109
Outcomes With Warfarin in Atrial Fibrillation
2026DOIPMID 42489390
A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial
2026DOI
A Scandinavian Perspective of the Projected Lifetime Cost-Effectiveness of Rivaroxaban Plus Aspirin in the COMPASS Trial
2026DOI
A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Duke University
Source: OpenAlex · retrieved 2026-09-29